exscientia

Recursion and Exscientia Merge, Create New Drug Discovery Company

US-headquartered biotech firm Recursion has announced that it will acquire UK-based pharmatech Exscientia in an all-stock deal. The transaction, which is expected to close in early 2025, would provide the combined entity with approximately $850 million in cash to fund its operations for the next three years. Reuters reported that Recursion will pay $688 million for the acquisition of Exscientia.

Exscientia Takes AI Specialist Allcyte

UK-based pharmatech Exscientia has entered into a binding agreement to buy Vienna-based Allcyte, a specialist in precision medicine using artificial intelligence (AI). Under the terms, Exscientia will pay €50 million, comprised of cash and Exscientia’s ordinary shares. The transaction is currently under review by Austrian regulators.

GSK Signs AI Pact with Exscientia

Sanofi and Exscientia in Metabolic Alliance